106 related articles for article (PubMed ID: 17041799)
1. New ambulatory implant technique of high-dose-rate interstitial brachytherapy for prostate cancer.
Yoshida K; Nose T; Shiomi H; Yoshioka Y; Fujita Y; Kuroda S; Yoshida M; Takahashi T; Kitamura M; Akai H; Oka T; Hosoki T
Radiat Med; 2006 Oct; 24(8):595-9. PubMed ID: 17041799
[TBL] [Abstract][Full Text] [Related]
2. Needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer.
Yoshida K; Yamazaki H; Nose T; Shiomi H; Yoshida M; Mikami M; Takenaka T; Kotsuma T; Tanaka E; Kuriyama K; Harada Y; Tohda A; Yasunaga Y; Oka T
Brachytherapy; 2010; 9(1):36-41. PubMed ID: 19736046
[TBL] [Abstract][Full Text] [Related]
3. New implant technique for separation of the seminal vesicle and rectal mucosa for high-dose-rate prostate brachytherapy.
Yoshida K; Kuroda S; Yoshida M; Fujita Y; Sakai M; Nohara T; Kawashima A; Takahashi T; Tohda A; Oka T; Yamazaki H; Kuriyama K
Brachytherapy; 2007; 6(3):180-6. PubMed ID: 17606414
[TBL] [Abstract][Full Text] [Related]
4. Assessment of daily needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer using daily CT examinations.
Takenaka T; Yoshida K; Ueda M; Yamazaki H; Miyake S; Tanaka E; Yoshida M; Yoshimura Y; Oka T; Honda K
J Radiat Res; 2012; 53(3):469-74. PubMed ID: 22485020
[TBL] [Abstract][Full Text] [Related]
5. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
[TBL] [Abstract][Full Text] [Related]
6. Role of novel risk classification method, Prostate Cancer Risk Index (PRIX) for clinically localized prostate cancer after high-dose-rate interstitial brachytherapy as monotherapy.
Yoshida K; Yamazaki H; Nakamura S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshioka Y
Anticancer Res; 2014 Jun; 34(6):3077-81. PubMed ID: 24922676
[TBL] [Abstract][Full Text] [Related]
7. Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy.
Mullokandov E; Gejerman G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1063-71. PubMed ID: 15001246
[TBL] [Abstract][Full Text] [Related]
8. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
9. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.
Zamboglou N; Tselis N; Baltas D; Buhleier T; Martin T; Milickovic N; Papaioannou S; Ackermann H; Tunn UW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):672-8. PubMed ID: 22929859
[TBL] [Abstract][Full Text] [Related]
10. Applicability and dosimetric impact of ultrasound-based preplanning in high-dose-rate brachytherapy of prostate cancer.
Aebersold DM; Isaak B; Thalmann G; Behrensmeier F; Kolotas C; Kranzbühler H; Mini R; Greiner RH
Strahlenther Onkol; 2004 Jun; 180(6):351-7. PubMed ID: 15175869
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
Hsu IC; Bae K; Shinohara K; Pouliot J; Purdy J; Ibbott G; Speight J; Vigneault E; Ivker R; Sandler H
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):751-8. PubMed ID: 20207506
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy.
Henry AM; Rodda SL; Mason M; Musunuru H; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):382-6. PubMed ID: 25805312
[TBL] [Abstract][Full Text] [Related]
13. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup.
Koutrouvelis PG; Lailas N; Katz S; Sehn J; Gil-Montero G; Khawand N
J Urol; 2003 Apr; 169(4):1331-6. PubMed ID: 12629354
[TBL] [Abstract][Full Text] [Related]
15. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
16. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
[TBL] [Abstract][Full Text] [Related]
17. Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy.
Komiya A; Fujiuchi Y; Ito T; Morii A; Yasuda K; Watanabe A; Nozaki T; Iida H; Nomura K; Fuse H
Int J Urol; 2013 Feb; 20(2):185-92. PubMed ID: 22905941
[TBL] [Abstract][Full Text] [Related]
18. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
19. Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer.
Yoshida K; Yamazaki H; Nakamara S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshioka Y
Anticancer Res; 2014 Apr; 34(4):2015-8. PubMed ID: 24692740
[TBL] [Abstract][Full Text] [Related]
20. [Physical basics and clinical realization of interstitial brachytherapy of the prostate with iodine 125].
Kaulich TW; Lamprecht U; Paulsen F; Kahmann F; Maurer U; Henkel TO; Loeser W; Bichler KH; Nüsslin F; Bamberg M
Strahlenther Onkol; 2002 Oct; 178(10):548-55. PubMed ID: 12386786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
